138 related articles for article (PubMed ID: 16338342)
1. Amyloid imaging: from benchtop to bedside.
Wu C; Pike VW; Wang Y
Curr Top Dev Biol; 2005; 70():171-213. PubMed ID: 16338342
[TBL] [Abstract][Full Text] [Related]
2. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.
Kung MP; Hou C; Zhuang ZP; Skovronsky D; Kung HF
Brain Res; 2004 Oct; 1025(1-2):98-105. PubMed ID: 15464749
[TBL] [Abstract][Full Text] [Related]
3. Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease?
Nichols L; Pike VW; Cai L; Innis RB
Biol Psychiatry; 2006 May; 59(10):940-7. PubMed ID: 16487944
[TBL] [Abstract][Full Text] [Related]
4. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829
[TBL] [Abstract][Full Text] [Related]
5. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
Fagan AM; Mintun MA; Mach RH; Lee SY; Dence CS; Shah AR; LaRossa GN; Spinner ML; Klunk WE; Mathis CA; DeKosky ST; Morris JC; Holtzman DM
Ann Neurol; 2006 Mar; 59(3):512-9. PubMed ID: 16372280
[TBL] [Abstract][Full Text] [Related]
6. [Introduction to and general remarks on molecular imaging].
Fukuda H; Okamura N
Brain Nerve; 2007 Mar; 59(3):203-7. PubMed ID: 17370645
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.
Mathis CA; Wang Y; Holt DP; Huang GF; Debnath ML; Klunk WE
J Med Chem; 2003 Jun; 46(13):2740-54. PubMed ID: 12801237
[TBL] [Abstract][Full Text] [Related]
8. Detecting amyloid-β plaques in Alzheimer's disease.
Baltes C; Princz-Kranz F; Rudin M; Mueggler T
Methods Mol Biol; 2011; 711():511-33. PubMed ID: 21279620
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain.
Zhen W; Han H; Anguiano M; Lemere CA; Cho CG; Lansbury PT
J Med Chem; 1999 Jul; 42(15):2805-15. PubMed ID: 10425090
[TBL] [Abstract][Full Text] [Related]
10. 11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
Serdons K; Verduyckt T; Vanderghinste D; Borghgraef P; Cleynhens J; Van Leuven F; Kung H; Bormans G; Verbruggen A
Eur J Med Chem; 2009 Apr; 44(4):1415-26. PubMed ID: 18992967
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research.
Jack CR; Marjanska M; Wengenack TM; Reyes DA; Curran GL; Lin J; Preboske GM; Poduslo JF; Garwood M
Neuroscientist; 2007 Feb; 13(1):38-48. PubMed ID: 17229974
[TBL] [Abstract][Full Text] [Related]
12. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.
Opazo C; Luza S; Villemagne VL; Volitakis I; Rowe C; Barnham KJ; Strozyk D; Masters CL; Cherny RA; Bush AI
Aging Cell; 2006 Feb; 5(1):69-79. PubMed ID: 16441845
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
[TBL] [Abstract][Full Text] [Related]
14. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile.
Agdeppa ED; Kepe V; Petri A; Satyamurthy N; Liu J; Huang SC; Small GW; Cole GM; Barrio JR
Neuroscience; 2003; 117(3):723-30. PubMed ID: 12617976
[TBL] [Abstract][Full Text] [Related]
15. [(18)F]-labeled isoindol-1-one and isoindol-1,3-dione derivatives as potential PET imaging agents for detection of beta-amyloid fibrils.
Lee JH; Byeon SR; Kim Y; Lim SJ; Oh SJ; Moon DH; Yoo KH; Chung BY; Kim DJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5701-4. PubMed ID: 18835777
[TBL] [Abstract][Full Text] [Related]
16. Abeta amyloid deposition in the language system and how the brain responds.
Nelissen N; Vandenbulcke M; Fannes K; Verbruggen A; Peeters R; Dupont P; Van Laere K; Bormans G; Vandenberghe R
Brain; 2007 Aug; 130(Pt 8):2055-69. PubMed ID: 17586869
[TBL] [Abstract][Full Text] [Related]
17. Visualizing pathology deposits in the living brain of patients with Alzheimer's disease.
Kepe V; Huang SC; Small GW; Satyamurthy N; Barrio JR
Methods Enzymol; 2006; 412():144-60. PubMed ID: 17046657
[TBL] [Abstract][Full Text] [Related]
18. [Neuroimaging Alzheimer's disease: early diagnosis, monitoring, and mechanism understanding].
Chételat G
Med Sci (Paris); 2011 Feb; 27(2):193-8. PubMed ID: 21382329
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease.
Kantarci K
Expert Rev Neurother; 2005 Sep; 5(5):663-70. PubMed ID: 16162090
[TBL] [Abstract][Full Text] [Related]
20. 2-Arylimidazo[2,1-b]benzothiazoles: a new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain.
Alagille D; DaCosta H; Baldwin RM; Tamagnan GD
Bioorg Med Chem Lett; 2011 May; 21(10):2966-8. PubMed ID: 21458990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
